A 59-year-old male is admitted to the hospital due to progressive fatigue, abdominal diste… — USMLE Step 2 CK

A $59$ -year-old male is admitted to the hospital due to progressive fatigue, abdominal distension, and reduced urine output over the past five days. He has a history of cirrhosis secondary to nonalcoholic steatohepatitis. One week ago, his outpatient diuretic regimen of spironolactone and furosemide was increased to manage worsening ascites. Vital signs on admission show a temperature of $37.0^\circ\text{C}$ ( $98.6^\circ\text{F}$ ), blood pressure of $98/58\text{ mm Hg}$ , and pulse of $88/\text{min}$ . Physical examination reveals shifting dullness and trace bilateral pedal edema, but no signs of asterixis or hepatic encephalopathy.

Laboratory studies on admission reveal:
- Serum sodium: $131\text{ mEq/L}$
- Serum creatinine: $2.6\text{ mg/dL}$ (baseline $1.0\text{ mg/dL}$ one month ago)
- Blood urea nitrogen: $54\text{ mg/dL}$
- Urinalysis: normal, with a fractional excretion of sodium (FENa) less than $1\%$
- Ascitic fluid analysis: $150\text{ neutrophils/mm}^3$

All diuretics are immediately discontinued, and he is treated with an intravenous infusion of albumin ( $1\text{ g/kg/day}$ ) for $48$ hours. Re-evaluation today shows a serum creatinine of $2.7\text{ mg/dL}$ . Renal ultrasound shows normal-sized kidneys with no hydronephrosis. Which of the following is the most appropriate next step in management?

Initiation of midodrine and octreotide therapyAnswer
B
Intravenous administration of broad-spectrum antibiotics
C
Restarting intravenous furosemide therapy
D
Therapeutic large-volume paracentesis
E
Initiation of continuous renal replacement therapy

Answer

Initiation of midodrine and octreotide therapy

This patient's clinical picture is classic for Hepatorenal Syndrome (HRS), a severe form of prerenal acute kidney injury seen in advanced cirrhosis. The diagnosis requires a rising serum creatinine that does not improve after at least 48 hours of diuretic withdrawal and volume expansion with albumin. It also requires the absence of shock, nephrotoxins, or intrinsic parenchymal kidney disease (confirmed by normal ultrasound and benign urinalysis). The pathogenesis of HRS involves severe splanchnic vasodilation leading to decreased effective arterial blood volume and extreme compensatory renal vasoconstriction. The most appropriate next step in management is the administration of splanchnic vasoconstrictors. In non-ICU settings, the combination of oral midodrine (an alpha-1 adrenergic agonist) and subcutaneous or intravenous octreotide (a somatostatin analog), along with continued intravenous albumin, is the standard of care to reverse vasodilation and improve renal perfusion.

Step-by-Step Solution

Analyze the initial presentation and laboratory findings.

The patient has cirrhosis, ascites, and a sharply rising serum creatinine (

2.6\text{ mg/dL}

) with a low FENa (

<1\%

) and normal urinalysis.

To establish the presence of acute kidney injury (AKI) of a prerenal etiology without intrinsic parenchymal kidney disease.

Evaluate the patient's response to the initial fluid resuscitation trial.

Renal function did not improve (creatinine rose to

2.7\text{ mg/dL}

) after

48

hours of diuretic withdrawal and volume expansion with intravenous albumin.

To differentiate simple volume-responsive prerenal azotemia from Hepatorenal Syndrome (HRS), which is notoriously unresponsive to fluids alone.

Select the most appropriate evidence-based pharmacological intervention.

Splanchnic vasoconstrictors (e.g., midodrine and octreotide) combined with continued albumin are identified as the next step.

HRS is driven by extreme splanchnic vasodilation. Reversing this specific mechanism helps restore effective circulating volume and renal perfusion.

Key Concept

Diagnosis and management of Hepatorenal Syndrome (HRS) using splanchnic vasoconstrictors and albumin.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic